

UNSTRUCTURED DATA UNIVERSITY AT BUFFALO

Peter L. Elkin, MD, MACP, FACMI, FNYAM
Director, Informatics Core of the UB CTSA
Professor and Chair, Department of Biomedical Informatics
Professor of Internal Medicine
Professor of Surgery
Professor of Pathology and Anatomical Sciences



Sources of Unstructured Data

- **Documents**
- **Reports**
- **Legions of Figures**
- **Tabular data names**
- **Field names in databases**

Some Datatypes are Only accessible from Unstructured Data

- Social Determinants of Health
- Signs and Symptoms
- Physical Exam findings
- Counseling
- Quality of Life
- Behavioral Data
- Street drug use
- Opinions

Electronic Health records

- Began in the 1960's
 - HELP – Utah
 - CoSTAR – MGH
- Commercial Systems
 - Technicon – from Lockheed 1963 developed for El Camino Hospital used NIH clinical center – and later became TDS (Han Article)
 - Meditech – 1969
 - 1977 MUM{PS was developed as a standard
 - 1979 – Epic started as an outpatient system
 - 1979 – Cerner which started as a lab system
 - 1980s – Boston Beth Israel System
 - 1980 – Regenstrief Institute of Indiana University
 - 1981 – VA Distributed Hospital Computing Program
 - 1994 – DHCP became VistA
 - 1994 – CPRS
 - 2009 – ARRA EHR Adoption



Electronic Health records Functional Specification from HL7

Population Health Support (CP)

Direct Care (DC)

Supportive (S)

Info

Care Provision Support (CP)

Example child functions:

POP.1	Support for Health Maintenance, Preventive Care and Wellness	CP.1	Manage Clinical History
POP.2	Support for Epidemiological Investigations of Clinical Health Within a Population	CP.2	Render Externally-sourced Information
POP.3	Support for Notification and Response	CP.3	Manage Clinical History
POP.4	Support for Monitoring Response Notifications Regarding a Specific Patient's Health	CP.4	Manage Patient History
POP.5	Donor Management Support	CP.5	Manage Allergy, Intolerance and Adverse Reaction
POP.6	Measurement, Analysis, Research and Reports	CP.6	Manage Medication List
POP.7	Public Health Related Updates	CP.7	Manage Problem List
POP.8	De-Identified Data Request Management	CP.8	Manage Strengths List
POP.9	Support Consistent Healthcare Management of Patient Groups or Populations	CP.9	Manage Immunization List
POP.10	Manage Population Health Study-Related Identifiers	CP.10	Manage Medical Equipment, Prosthetic/Orthotic, List
		CP.6.1	Manage Patient and Family Preferences
		CP.6.2	Manage Templates
		CP.6.3	Manage & Immunization Orders
		CP.6.4	Manage Vaccination Interaction & Allergy Checking
			Manage Specific Dosing and Warnings
			Manage Ordering Efficiencies
			Manage Recommendations
		CPS.8	Support Patient Education
		CPS.9	Support Care Coordination
		CPS.4.3	Support for Non-Medication Ordering
		CPS.4.4	Support Orders for Diagnostic Tests
		CPS.4.5	Support Orders for Blood Products and Other Biologics



Best in KLAS: Software

Category	Recipient
Acute Care EMR (Large Hospital/IDN)	Epic EpicCare Inpatient EMR
Anesthesia	iProcedures iPro Anesthesia
Cardiology	Merge, an IBM Company, Cardio
Community HIS	MEDITECH C/S Community HIS (6.x)
Emergency Department	Wellsoft EDIS
Enterprise Resource Planning (ERP)	Premier PremierConnect ERP Solutions
Global (Non-US) Acute Care EMR	InterSystems TrakCare EPR
Global (Non-US) PACS	Sectra PACS
Global (Non-US) Patient Administration Systems	InterSystems TrakCare PAS
Health Information Exchange (HIE)	Epic Care Everywhere
Healthcare Business Intelligence & Analytics	Health Catalyst Analytics Platform
Homecare	Thornberry NDoc
Laboratory (Large Hospital/IDN)	Epic Beaker
Long-Term Care	MatrixCare
PACS (Large Hospital/IDN)	Sectra PACS
Patient Access	Experian Health eCare NEXT
Patient Accounting & Patient Management (Large Hospital/IDN)	Epic Resolute Hospital Billing
Patient Portals	Epic MyChart
Population Health	Enli CareManager i2i Population Health i2iTracks
Speech Recognition—Front-End	MModal Fluency Direct
Surgery Management	Cerner Surgical Management
VNA/Image Archive	Merge, an IBM Company, iConnect Enterprise Archive

High Performance Computing and Natural Language Understanding

Peter L. Elkin¹, Daniel R Schlegel², Christopher Crowner¹, Frank LeHoullier¹

¹*Department of Biomedical Informatics, University at Buffalo, SUNY, Buffalo ,NY USA*

²*SUNY Oswego, New York USA*



Introduction

Big data is expanding exponentially. We are looking at housing, processing, analyzing and retrieving

Petabytes of data every day. With the advent of Genomic and Proteomic data we are increasingly challenged with understanding the patient's phenotype with greater specificity and detail. This is going to require developing and applying ontology at a more granular and consistent fashion.

Methods

The UB Center for Computational Research (CCR) is an NSF sponsored supercomputing facility where we can scale to 16,000 nodes. We have a large number of high memory (>64GB) nodes. We installed a script to access the CCR scheduling application and deployed our HTP application (See Figure 1).




Results


We have 212,343 patients in our observational database. We have 7,000,000 clinical notes and reports and they have generated 750,000,000 SNOMED CT codes. Structured data are held in SQLServer™ in OMOP / OHDSI format. The ontology codes such as in SNOMED CT are held in a Berkley DB, NOSQL database. The compositional expressions are held in Neo4J (a graph database) and also in Graph DB (a triple store). Our retrieval times for real clinical questions average between 2 and 3 seconds.

Observational Data are formatted for OMOP (OHDSI) and i2b2


The Evolution of Modern Data Engineering



Medical Ontology : Relationships between diseases, disorders, & systems, organs and tissues




Biomedical Ontology : Neuronal interaction between diseases, systems, organs, substances, tissues, cells, proteins and genetics



Basic Formal Ontology (BFO)


Defines the high-level structures common to all domains
Connects → Health – Basic Science – Finance & Engineering



- Cell Ontology (NHGRI, NIAID)
- eagle-i and VIVO (NCATS)
- Environment Ontology (GSC)
- Gene Ontology (NHGRI)
- IDO Infectious Disease Ontology (NIAID)
- Nanoparticle Ontology (PNNL)
- Ontology for Risks Against Patient Safety (EU)
- Ontology for Pain, Mental Health and Quality Of Life (NIDCR)
- Plant Ontology (NSF)
- Protein Ontology (NIGMS)
- Translational Medicine Ontology (W3C)
- US Army Biometrics Ontology (DOD)
- Vaccine Ontology (NHBLI)

Ceusters W, Elkin P, Smith B. Negative findings in electronic health records and biomedical ontologies: a realist approach. Int J Med Inform. 2007 Dec;76 Suppl 3:S326-33.

Ontology of General Medical Sciences (OGMS)



Level Three Ontology


- Fully Encoded Health Record
- Consistent with the Level One and Two Ontologies for Health
- Compositional Expressions are assigned Automagically
- Information is gathered through the usual documentation of patient care.
- Example.....

SNOMED Codes:

1	Type 2 [M] (258195006)	Diabetes mellitus [K] (73211009)	[Retinopathy [K] (399625000)]	Type 2 [M] (258195006)	Diabetes mellitus [K] (73211009)	Kidney disease [K] (90708001)	Type 2 [M] (258195006)
	Type ii	dm	with	retinopathy	Type ii	dm	with
	Diabetes mellitus [K] (73211009)	Neuropathy [K] (386033004)	Pneumonia [K] (233604007)	Pneumonia	with	Sepsis	Hypertensive heart disease
	dm	with	neuropathy			Hypertensive heart disease	with
	Condition [M] (260905004)	Proliferative diabetic retinopathy [K] (59276001)				Drug-induced cirrhosis of liver [K] (425413006)	
	due to underlying	condition	with	proliferative diabetic retinopathy	with macular edema	Alcoholic cirrhosis of liver	Cirrhosis of liver [K] (19943007)
	Systole, function [M] (111973004)	Congestive heart failure [K] (42343007)	and	Diastolic blood pressure [M] (271650006)	Congestive heart failure [K] (42343007)	Alcoholic hepatic failure [K] (235881000)	Bronze cirrhosis [K] (399126000)
	systolic	congestive heart failure		diastolic	chf	Alcoholic hepatic failure	Alcoholic cirrhosis [K] (420054005)
	combined					with	Ascites [K] (389026000)
							Sudden [M] (255363002)
							Acute
							combined
							Coma [K] (371632003)
							coma

Compositional Expressions:

1	Type 2 [M] (258195006)	Diabetes mellitus [K] (73211009)	[Retinopathy [K] (399625000)]	Type 2 [M] (258195006)	Diabetes mellitus [K] (73211009)	Kidney disease [K] (90708001)	Type 2 [M] (258195006)
	Type ii	dm	with	retinopathy	Type ii	dm	with
	Diabetes mellitus [K] (73211009)	Neuropathy [K] (386033004)	Pneumonia [K] (233604007)	Pneumonia	with	Sepsis	Hypertensive heart disease
	dm	with	neuropathy			Hypertensive heart disease	with
	Condition [M] (260905004)	Proliferative diabetic retinopathy [K] (59276001)				Drug-induced cirrhosis of liver [K] (425413006)	
	due to underlying	condition	with	proliferative diabetic retinopathy	with macular edema	Alcoholic cirrhosis of liver	Cirrhosis of liver [K] (19943007)
	combined	systolic	congestive heart failure	and	diastolic	chf	Bronze cirrhosis [K] (399126000)
							Alcoholic hepatic failure [K] (235881000)
							Alcoholic hepatic failure
							with
							Coma [K] (371632003)
							coma



Case

HISTORY OF PRESENT ILLNESS:

#1 Chest pain

Patient is a 57-year old gentleman with a 80-pack-year smoking history. He has a family history of early coronary disease on his father's side, as his father had a heart attack at age 43. Patient does not exercise very much. He drinks 2 ounces of alcohol a day. He has type ii diabetes mellitus, hypertension, nor does he know his cholesterol level. Patient was in his usual state of health until 2 months ago when he began having exertional dyspnea and chest pain at peak exercise. Patient could walk 4 blocks and up 2 flights of stairs before he would have crushing substernal chest pain, which radiated to his left arm. On a scale of 0 to 10, it was as bad as 8 out of 10. Patient had some diaphoresis and dyspnea associated with the chest pain. He would sit down and this would be relieved after about 15 minutes. Patient has taken it upon himself to limit his activities based on this symptomatology. Patient has an interest in quitting smoking. He denies palpitations, syncope, pre-syncope, PND, or orthopnea. Patient has had no peripheral edema or shortness of breath at rest. He has had no episodes where the pain lasted greater than one-half hour.

#2 Right knee pain

Patient has had an 8-year history of right knee pain. Patient works as a construction worker and had a fork lift injury 8 years ago. Since that time, he has had more difficulty getting around on his right knee. It pops occasionally, but it never locks. It has not given out on him, but he has constant pain for which he takes ibuprofen on a regular basis. Patient used to be an avid golfer, but he has not been able to participate since the injury. This has also effected his work, as he has had difficulty climbing which is sometimes required in his profession.

#3 Nicotine dependence

Patient smokes a pack a day and has a 80-pack-year smoking history. He was smoking less than this until last year. Patient states his stress at work is the factor that has caused an increase in smoking, and he will be willing to see the Nicotine Dependence Center. In the past, he has tried to quit on his own without help of nicotine patches or any other nicotine replacement or Wellbutrin.

#4 Obesity

Patient is somewhat overweight and has had difficulty losing weight despite being a smoker. Patient has tried dieting and exercising programs, but since his inability to exercise with the right knee injury, he has had more difficulty with exercise and has not been able to lose weight. Patient states he watches his diet quite closely and has been limiting his caloric intake. To that end, he has actually lost 8 pounds over the last 6 months.

#5 Diabetes Mellitus Type ii

Patient denies polyuria and polydipsia however he is well controlled with Levemir Insulin 28 U SQ bid and Metformin 1000 mg bid. He has peripheral diabetic neuropathy, nephropathy and retinopathy.

Physical Examination (Relevant Sections)

- Extremities – Without clubbing, cyanosis, or edema. + Neuropathy with 3+/5+ loss of sensation in both feet to the ankle.
- Neuro – Cranial nerves 2 through 12 were intact. Visual fields were within normal limits. Pupils were equal and reactive to light and accomodation. Sensation was intact and bilaterally symmetric in his arms but a loss of sensation was found in his feet using a microfilliment examination. Motor was 5+/5+ bilaterally symmetric. Deep tendon reflexes were 2+/2+ and were symmetric bilaterally. Romberg was normal. Cerebellar signs were absent. Babinski was down going bilaterally.

History Encoded in SNOMED CT

He	drinks	2	ounces	of	alcohol	a	day	.
He has	type ii diabetes mellitus	,	hypertension	,	nor does he know his	cholesterol level	,	
Patient	was in his usual	state	of	health	until 2	months	ago when he began having	
Patient	were	peak	Exercise	exercise			Dyspnea on exertion [K] (60845006)	Chest pain [K] (29857009) hasModif
Patient	could walk 4 blocks and up 2 flights of stairs before he would have crushing substernal							
Patient	had some	diaphoresis	and	dyspnea	associated with the		Chest pain [K] (29857009)	Entire left upper arm [M] (72098002)
Patient	has taken it upon himself to limit his	activities	based on this symptomatology .					
Patient	has an interest in quitting	smoking						
He denies	palpitations	,	syncope	,	pre	-	syncope	,
Patient	has had no	peripheral edema	or	shortness of breath	at	rest		

History

5 Diabetes mellitus type 2 [K] (44054006) Patient [M] (116154003) Polyuria [K] (28442001) Psychogenic polydipsia [K] (15945005) Insulin [K] (67866001)
Diabetes Mellitus Type ii Patient denies polyuria and polydipsia however he is well controlled with Levemir Insulin 28
Lower case Roman letter u [M] (257999003) Subcutaneous [M] (263887005) Metformin [K] (109081006) milligram [M] (258684004)
U SQ bid and Metformin 1000 mg bid .
Peripheral [M] (14414005) Diabetic neuropathy [K] (230572002) Kidney disease [K] (90708001) Retinopathy [K] (399625000)
He has peripheral diabetic neuropathy , nephropathy and retinopathy . ,

Extremities – Without clubbing, cyanosis, or edema.
+ Neuropathy with 3+ / 5 + loss of sensation in both feet to the ankle.
Neuro – Cranial nerves 2 through 12 were intact.
Visual fields were within normal limits.
Pupils were equal and reactive to light and accommodation.
Sensation quality was intact and bilaterally symmetric in his arms but a loss of sensation was found in his feet using a microfilliment.
Examination - action examination.
Efferent was 5+ / 5 + bilaterally symmetric.
Deep tendon reflexes were 2+ / 2+ and were symmetric bilaterally.
Romberg was normal.
Cerebellar signs were absent.
Babinski was down going bilaterally.
Gait function – Within normal limits.

Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes

The purpose of this study is to assess how glucagon administered as a puff into the nose (AMG504-1) works in children and adolescents compared with commercially-available glucagon given by injection. In addition, the safety and tolerability of glucagon given as a puff into the nose will be evaluated.

Part-of-Speech:

	DT	NN	IN	DT	NN	VBZ	TO	VB	WRB	NN	VBN	IN	DT	NN	IN	DT	NN	JJ	NN	CD	VBZ	IN	NNS	CC	NN	VBN	IN	RB	JJ								
1	The	purpose	of	this	study	is	to	assess	how	glucagon	administered	as	a	puff	into	the	nose	(AMG504	-	1)	works	in	children	and	adolescents	compared	with	commercially	-	available	glucagon	given	by	injection	.
2	In	addition	,	the	safety	and	tolerability	of	glucagon	given	as	a	puff	into	the	nose	will	be	evaluated	.	,																

SNOMED Codes:

	Purpose [M] (246099003)	Study [M] (224699009)	Glucagon product [K] (10712003)	Puff - unit of product usage [M] (415215001)	Entire nose [M] (181195007)
1	The purpose of this study is to assess how	glucagon administered as a	puff into the nose	Entire nose	(
	AMG504 - 1) works in children and adolescents	compared with commercially - available glucagon given by injection	Injection	.	
2	In addition , the safety and tolerability of glucagon given as a	puff into the nose	Entire nose	will be evaluated . ,	

Rational Knowledge Representation

- Cellulitis of the left foot with Osteomyelitis of the Third metatarsal without Lymphangitis

[AND]

[WITH]

[Cellulitis \(disorder\) \[128045006\]](#)

[has Finding Site]

[Entire foot \(body structure\) \[302545001\]](#)

[has Laterality]

[Left \(qualifier value\) \[7771000\]](#)


[Osteomyelitis \(disorder\) \[60168000\]](#)

[has Finding Site]

[Entire third metatarsal \(body structure\) \[182134006\]](#)

[WITHOUT]

[Lymphangitis \(disorder\) \[1415005\]](#)





Case One


Case Two

Semantic Network

Multi-Center Data
Sharing and
Interchange










Intelligent Agents

The Evolution of Healthcare






CTSI Biomedical Informatics Core Facility Architecture




Precision Oncology (POP) – Big Picture

MAVERIC Precision Oncology Program
High Level Conceptual Design with VistA Evolution



Learning Healthcare System Model



SHOTGUN MULTITARGET DRUG DISCOVERY PIPELINE


Knowledge based
fragment docking with
dynamics




Systems based
multitarget
drug discovery



Prospective validation
followed by clinical
studies, other
applications



Indication	Putative primary cause	Validations (total)	Hit rate (current) [★ = <i>in vivo</i>]	Source / Collaborator	Reference (or TBP)
Diabetes mellitus type 1	autoimmune, genetic	10	1/1 ★	Gaurav Chopra, UCSF	TBP
Dental caries	<i>S. mutans</i>	10	10/10	Jeremy Horst, UCSF	[5, 22], TBP
Dengue fever	Dengue virus	31	11/27	Scott Michael, FGCU	TBP
Herpes	HSV, CMV, KSHV (all)	29	6/29	Michael Lagunoff, UW; ImQuest Biosciences, Inc.	TBP
MDR Tuberculosis	<i>M. tuberculosis</i>	17	4/8	Michael Strong, NJHC	TBP
Systemic lupus erythematosus	autoimmune	≈20	1/1	Keith Elkon, UW	TBP
PB cirrhosis	HBRV	≈20	12 / 12	Andrew Mason, U. Alberta	TBP
Hepatitis B	Hepatitis B virus	31	3 / 31	ImQuest Biosciences, Inc.	[14], TBP
Flu	Influenza A virus	24	0 / 24	ImQuest Biosciences, Inc.	[14], TBP
AIDS	HIV 1 & 2	≈40	ongoing	James Mullins, UW	
Diabetes mellitus type 2	metabolic, genetic	≈80	ongoing	Jay Heinecke, UW	
Cholangiocarcinoma	neoplastic disorder	40	ongoing	Natini Jinawath, Ramathibodi Hospital, Thailand	
Ebola hemorrhagic fever	Ebola virus	≈40	ongoing	Michael Katze, UW	
Flu	Influenza viruses	≈40	ongoing	various	
Hepatitis C	Hepatitis C virus	≈20	ongoing	Lorne Tyrell, U. Alberta	
MDR Tuberculosis	<i>M. tuberculosis</i>	40	ongoing	Prasit Palittapongarnpim, Mahidol U, Thailand	
Soft tissue infections	<i>P. aeruginosa</i>	≈40	ongoing	Pradeep Singh, UW	
Yellow fever	Yellow fever virus	≈20	ongoing	Scott Michael, FGCU	



HTP-NLP & CANDO / CANDOCK

Clinical



Functional:
Metabolome

Structural:
Proteome and
Small

Structure and
Function = Accurate
Predictions => Bench
Validations

A

B

Modeled or experimental
protein structure



Ligand Library



Protein-drug ligand

Matrix of binding affinities

Top novel predictions



Drug or other ligand

Ram Samudrala, PhD




Computational to Validation Components

Empirical / data-driven





Building from data

Combinatorial profiling



Mechanistic/ first principles



Lung Organoid

- Data mgt/ integration/ normalization
- Feature identification/ pattern matching
- Network Generation
- Statistical inference / diagnostic classification

- Literature Based Discovery
- Mining basic principles (NLP)
- Causal regulatory dynamics
- Simulation/ optimal trial design

Evaluation of Candidate Drugs
1. Cell lines
2. Organoids/Spheroids
3. PDX tumors



Phase I Clinical Trials



Healthcare Value

- **Value = Quality / Cost**
- **Quality is composed of:**
 - Outcomes
 - Safety
 - Service
 - Reliability



Measuring Strategic Performance

“You can’t manage what you can’t measure. You can’t measure what you can’t describe”


Robert Kaplan and David Norton
Authors of “The Balanced Scorecard”



Framework that **aligns the entire organization** to what is **important to the customer**, allowing the organization to **excel** at the **critical activities** and **reduce time spent** on the **things that don't matter**



People



Process



Technology

BMI Investigator

Search Results

Clinic Num

Total records = 0
 Page 0 of 0

Export Results

Visualize

AND OR

Manifestation ▾ equal ▾

Concept Description

Anxiety

Terminology Server

SNOMED

Sign

POSITIVE ▾

Explode

True

Section

ASSESSMENT

CHIEF_COMPLAINT

COUNSELING

DISCUSSION_SUMMARY



Include ▾

Value

No

Time

No

Reset

Query

Export Query

Import Query

Search

Elapsed time: 18.773

BMI Investigator

Search Results

Clinic Num

18001

180047

180101

180111

180117

180119

180114

180204

180000

18001

Total records = 32798

Page 1 of 4280

1 2 3 4 5 6 7 8 9 10 ...

Export Results

Visualize

+ Add rule

0 Add group

X Delete

AND OR

.....

Reset

Query

Export Query


Import Query

Search


Elapsed time: 18.773

Elapsed time: 0

A N X I E T Y



Study: Are patients with Rosacea at increased risk of having Obstructive Sleep Apnea?



Clinical Predication Rule Validation Engine

Electronic Health
Record across all
EHRs by using a
common
observational
model (OMOP /
OHDSI)

Clinical Data Viewer

Import Research IDs

Import

Research ID

11808

Encounter ID

3837049
4128131
4128539
4854469
3118429
3744154
6138091
3128017
MARINA

Observations->CHA2DS2-VASc

CHF LVSD	<input type="checkbox"/>
Hypertension or HBP	<input type="checkbox"/>
DM	<input type="checkbox"/>
Stroke/Tia/Thromboembolism	<input type="checkbox"/>
Vascular Disease	<input type="checkbox"/>

Submit

Data

Note	Today	Duration	Medication	Diagnos
------	-------	----------	------------	---------

Chief Complaint:
Patient presents for a follow up visit.

History of Present Illness:
Continues smoking 5-6 cigarettes per day, does not want to quit.. Rx patent foramen ovale, needs refill for warfarin. All residual weakness from CVA has resolved.. Takes simvastatin for hyperlipidemia..

HPI Interim History:


Past Medical History:

Quality Accomplishments

- Improved Quality of Care
 - Metrics and Measurement of Practice Outcomes
 - Patient Centered Medical Home
 - Quality Improvement Project Registry
 - Improved outcomes in Payer Measures
- Improvement in Internal Referrals
 - Went from 54% to 82% Internal Referrals
- DOM Strategic Plan Implementation
 - Quality Tools
 - Quality Structures
 - Support of New Multispecialty Clinical and Research Centers

From third to the last to the best in IHA Quality metrics

Quality Compliance Rates - Adult TPC Groups




Period	Q2 2016
METRIC	QUALITY

Confidential

DATA SOURCE Quality Dashboard, VIPS
 TIME FRAME July 1 2015 - June 30 2016
 GROUP COUNT 26


Internal Medicine Provider Report Cards for Target Patient Populations

Provider O



All benchmarks are within a one year period. Patient counts are on a provider level, unless otherwise noted.

Provider	Practice
HbA1c <7	56.9% 46.6%
HbA1c 1 yr	80.0% 75.6%
LDL <100	33.8% 35.4%
LDL 1 yr	57.7% 58.7%
MAlb <30	39.2% 37.5%
MAlb 1yr	42.3% 40.9%
MAlb or Neph	53.1% 51.8%
Eye Exam	20.8% 22.8%



Goals for benchmarks are 85% or higher for labs, vaccinations and exams. An 8% improvement from year to year is also considered meeting goals.


Provider	Practice
Myocardial Infarction	3 Pts 47 Pts
Myo Inf on Beta	33.3% 21.3%
LDL Done 1yr	50.8% 59.5%
LDL <100	35.4% 41.8%
Diabetes or LVSD	22 Pts 219 Pts
Diab/LVSD on Ace/Arb	77.3% 67.1%

Internal Medicine Provider Report Cards for Target Patient Populations

Provider O



Patients Eligible for CRC Screening	496	Patients Eligible for Mammo Screening	423
Patients Eligible for Cervical Screening	584	Patients Eligible for Chlamydia Screening	54
Patients Eligible for Flu Shot	957	Patients Eligible for Pneumo Shot	264




Colorectal Screening is colonoscopy in the last 10 yrs or FOBT in the last 2 yrs for patients between 50 and 80. Mammogram Screening is reporting on women ages 42 to 69. Chlamydia Screening is reporting on patients between 18 and 24. Cervical Screening is Pap Smear in the last 3 yrs. Flu shot is done with in the last yr and Pneumo is a Pneumococcal vaccination lifetime

	Provider	Practice
CRC Screening	39.1%	39.0%
Mammo Screening	52.5%	56.0%
Chlamydia Screening	0.0%	2.9%
Cervical Cancer Screening	4.1%	5.4%
Flu shot 1yr	46.7%	35.0%
Pneumo	71.2%	74.0%


Internal Medicine Provider Report Cards for Target Patient Populations

Patients with Persistent Asthma 115



	Provider	Practice
Cortesteroid Inhaler Prescribed	47.8%	40.3%


Patients with COPD 38




	Provider	Practice
Spirometry Test Done 1 yr	0.0%	0.4%

Internal Medicine Provider Report Cards for Target Patient Populations

Provider O



All benchmarks are within a one year period. Patient counts are on a provider level, unless otherwise noted.



Goals for benchmarks are 85% or higher for labs, vaccinations and exams. An 8% improvement from year to year is also considered


Provider	Practice
Myocardial Infarction	1 Pts 13 Pts
Myo Inf on Beta	100.0% 69.2%
LDL Done 1 yr	60.3% 62.3%
LDL <100	44.9% 43.6%
Diabetes or LVSD	27 Pts 206 Pts
Diab/LVSD on Ace/Arb	63.0% 63.6%

Internal Medicine Provider Report Cards for Target Patient Populations

Provider O



Patients Eligible for CRC Screening	637	Patients Eligible for Mammo Screening	486
Patients Eligible for Cervical Screening	699	Patients Eligible for Chlamydia Screening	59
Patients Eligible for Flu Shot	1186	Patients Eligible for Pneumo Shot	361



	Provider	Practice
CRC Screening	53.5%	47.0%
Mammo Screening	57.0%	61.2%
Chlamydia Screening	28.8%	24.1%
Cervical Cancer Screening	7.7%	9.1%
Flu shot 1yr	34.5%	26.8%
Pneumo	90.3%	86.1%

Internal Medicine Provider Report Cards for Target Patient Populations

Patients with Persistent Asthma **159**


Asthma Benchmarks

■ Provider O

100%
80%
60%
40%
20%
0%

Cortesteroid Inhaler Prescribed

	Provider	Practice
Cortesteroid Inhaler Prescribed	47.2%	39.2%



Patients with COPD **13**


COPD Benchmarks


■ Provider O

100%
80%
60%
40%
20%
0%


Spirometry 1 yr

	Provider	Practice
Spirometry Test Done 1 yr	0.0%	1.8%







Diabetes Measures - DENT




Preventative Immunization Measures- DENT




Diabetes




Asthma/ COPD Measures - DENT



Preventative Screening Measures - DENT





Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes

The purpose of this study is to assess how glucagon administered as a puff into the nose (AMG504-1) works in children and adolescents compared with commercially-available glucagon given by injection. In addition, the safety and tolerability of glucagon given as a puff into the nose will be evaluated.

Part-of-Speech:

1 The purpose of this study is to assess how glucagon administered as a puff into the nose (AMG504 - 1) works in children and adolescents compared with commercially available glucagon given by injection .

2 In addition , the safety and tolerability of glucagon given as a puff into the nose will be evaluated . ,

SNOMED Codes:

	Purpose [M] (246099003)	Study [M] (224699009)	Glucagon product [K] (10712001)	Puff - unit of product usage [M] (415215001)	Entire nose [M] (181195007)
1	The purpose of this study is to assess how glucagon administered as a puff into the nose (
	Adolescent [M] (133937008)		Availability of [Q] (103328004)	Glucagon product [K] (10712001)	Injection [K] (59108006)
	AMG504 - 1) works in children and adolescents compared with commercially - available glucagon given by injection .				
2	Glucagon product [K] (10712001)	Puff - unit of product usage [M] (415215001)	Entire nose [M] (181195007)		
	In addition , the safety and tolerability of glucagon given as a puff into the nose will be evaluated . .				


Prescription Opioid Dependence in Western New York: Using Data Analytics to find an answer to the Opioid Epidemic

Shyamashree Sinha, Gale R Burstein, Kenneth E Leonard, Timothy F Murphy,
Peter L Elkin


Department of Biomedical Informatics/ Department of Anesthesiology
*Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, The State
University of New York, Buffalo, New York*




Distribution of Opioid Dependence among the Non-Hispanic community in the clinic population of Western New York





Distribution of Opioid Dependence based on geographical location



The distribution of the patients based on the first three numbers of the zip code showed area 142 had the highest number of opioid dependent population







Map showing boundaries of area with zip code 142:
<https://www.maptechnica.com/zip3-prefix-map/142>

AI AND NATURAL LANGUAGE PROCESSING (NLP) TO ENHANCE STRUCTURED DATA'S ABILITY TO IDENTIFY NONVALVULAR ATRIAL FIBRILLATION PATIENTS AND THEIR STROKE AND BLEEDING RISK

Peter L. Elkin, MD, MACP, FACMI, FNYAM
For the NVAF Surveillance Study team



Goal of the study

- The goal of this study is to compare clinician-rated stroke and bleed risk assessments in Nonvalvular Atrial Fibrillation (NVAF) patients with assessments utilizing NLP derived codified EHR data for CHA₂DS₂-VASc and HAS-BLED scores.

Research Questions

- ***Research Question: 1***
- What is the accuracy of using structured data (ICD and CPT and Medication codes) alone vs. unstructured (ie, Clinical notes and reports, labs and Medications) plus structured data to identify patients who have Atrial Fibrillation?
- ***Objectives:***
- Compare structured data to structured and unstructured data using NLP to identify NVAF Patients - validated by clinician assessment

Research Question 4

Does the method (using structured data only vs. structured plus unstructured data) of determining risk scores affect the treatment of NVAF patients for stroke prevention with OAC?

Objectives:

1. Using structured and unstructured data assessments of CHA₂DS₂-VASc, HAS-BLED scores and contraindications for OAC, classify the patient cohorts as follows and compare the treatment rates with OAC.
 1. Would benefit and are on OAC;
 2. Would benefit but are not on OAC;
 3. Would not benefit and are on OAC;
 4. Would not benefit and are not on OAC

Semi-Supervised Machine Learning

- Small Amount of Labeled Data and Large Amounts of Unlabeled Data
- Cheaper and Faster than a Fully Supervised Approach
- More accurate than an unsupervised approach
- Can be used to create models from a mixed dataset. These models can be used for Biosurveillance.
- Example:
 - Intuitively, we can think of the learning problem as an exam and labeled data as the few example problems that the teacher solved in class. The educator also provides a set of unsolved problems. In transductive reasoning, these unsolved problems are a take-home exam questions and you want to do well on them in particular. In inductive reasoning, these are practice problems of the sort you will encounter on the in-class exam.
- NSQIP - Murff HJ, FitzHenry F, Matheny ME, Gentry N, Kotter KL, Crimin K, Dittus RS, Rosen AK, Elkin PL, Brown SH, Speroff T. [Automated identification of postoperative complications within an electronic medical record using natural language processing.](#) JAMA. 2011 Aug 24;306(8):848-55.
- NVAF Study – in press, Circulation, 2017.

Result

Table 1. Comparison of outcomes for Structured and Structured plus Unstructured data against the gold standard.

Outcome	Structured	Structured+NLP	P
Sensitivity	.773 (.68, .79)	1 (.979,1)	<0.001
Specificity	.47 (.258, .65)	.444 (.279, .619)	0.317
PPV	.91 (.87, .95)	.93 (.893, .956)	0.007
NPV	.215(.131, .322)	1 (.713, 1)	<0.001
kappa	.156 (.041, .271)	.585 (.414, .733)	<0.001


- Out of the 96,681 patients identified in the AllScripts EHR database, 2.8% (2722 cases) were identified with NVAF by the Structured+NLP method as opposed to 1.9% for Structured alone (1849 cases) with a difference of 873 cases
- Out of the 96,681 patients identified in the AllScripts EHR database, 2.8% (2722 cases) were identified with NVAF by the Structured+NLP method as opposed to 1.9% for Structured alone (1849 cases) with a difference of 873 cases
- Based on the PPV adjusting the true positive rates for both ICD9 and NLP alone this converts to a 36.3 % improvement identification of true cases in this NVAF cohort.

Histograms of CHA₂DS₂-VASC Scores and HAS-BLED scores

Results:

Table 2.1. Pearson Product Moment

	Structured		Structured+NLP		
	estimate (95% CI)	p-value	estimate (95% CI)	p-value	
CHA₂DS₂-VASC Score	0.819 (0.775,0.855)	<.001	0.898 (0.872,0.92)	<.001	
HAS-BLED Score	0.688 (0.619,0.747)	<.001	0.717 (0.652,0.771)	<.001	



Sensitivity and Specificity of Outcomes Compared to Gold Standard			
HAS-BLED		CHA ₂ DS ₂ -VASC	
Method: McNemar		Method: Exact Binomial	
Sensitivity		Sensitivity	
Structured	0.382	Structured	0.942
Structured+NLP	0.806	Structured+NLP	0.983
Difference	0.424	Difference	0.0413
Test Statistic	72	Test Statistic	-
p-value	<.0001	p-value	0.00195
Method: McNemar		Method: Exact Binomial	
Specificity		Specificity	
Structured	0.947	Structured	0.955
Structured+NLP	0.777	Structured+NLP	0.909
Difference	-0.17	Difference	-0.0455
Test Statistic	16	Test Statistic	-
p-value	<.0001	p-value	1
Method: Generalized Score		Method: Generalized Score	
Positive Predictive Value		Positive Predictive Value	
Structured	0.929	Structured	0.996
Structured+NLP	0.867	Structured+NLP	0.992
Difference	.061	Difference	0.004
Test Statistic	4.487	Test Statistic	0.915
p-value	0.034	p-value	0.339
Negative Predictive Value		Negative Predictive Value	
Structured	0.459	Structured	0.6
Structured+NLP	0.689	Structured+NLP	0.833
Difference	0.23	Difference	0.233
Test Statistic	47.757	Test Statistic	11.662
p-value	<.00001	p-value	<0.001


Area under the Curves (AUC)

*C-Index and Somer's D using
 Ordinal Logistic Regression
 (where probabilities are modelled
 as $P(Y \geq k | X)$)
 (R rms and Hmisc packages)*

C-index Structured CHA_2DS_2 -VASC: 0.863 (CI:0.838, 0.887)
 (Somer's D (D_{xy}): 0.726,
 SD=0.025)

C-index Structured+NLP
 CHA_2DS_2 -VASC: 0.914 (CI:
 0.896, 0.933) (Somer's D (D_{xy}):
 0.829, SD=0.0185)
 $Z=0.625/.0316=19.776$

CHA_2DS_2 -VASC: Compared to
 Standard normal distribution*: **2-Sided p-value: <0.001**
1-Sided p-value: <0.001



Predictive Risk Model Generation of Requiring Rx with OAC and not being currently on treatment

		Would Benefit and On OAC	Would Benefit and Not on OAC	Would Not Benefit and Are on OAC	Would Not Benefit and Are Not on OAC
Gold Standard with Contraindication	CHA ₂ DS ₂ -VASc ≥2 AND HAS-BLED <3 and Contraindication	3	2	0	1
	CHA ₂ DS ₂ -VASc ≥2 AND HAS-BLED ≥ 3 and Contraindication	6	0	0	1
	CHA ₂ DS ₂ -VASc <2 and Contraindication	0	0	0	1
Gold Standard with No Contraindication	CHA ₂ DS ₂ -VASc ≥2 AND HAS-BLED <3 and No Contraindication	38	15	0	14
	CHA ₂ DS ₂ -VASc ≥2 AND HAS-BLED ≥ 3 and No Contraindication	129	16	1	16
	CHA ₂ DS ₂ -VASc <2 and No Contraindication	10	3	0	8
Structured with Contraindication	CHA ₂ DS ₂ -VASc ≥2 AND HAS-BLED <3 and Contraindication	4	1	0	0
	CHA ₂ DS ₂ -VASc ≥2 AND HAS-BLED ≥ 3 and Contraindication	3	1	0	0
	CHA ₂ DS ₂ -VASc <2 and Contraindication	0	0	0	0
Structured with No Contraindication	CHA ₂ DS ₂ -VASc ≥2 AND HAS-BLED <3 and No Contraindication	109	25	0	21
	CHA ₂ DS ₂ -VASc ≥2 AND HAS-BLED ≥ 3 and No Contraindication	49	5	0	11
	CHA ₂ DS ₂ -VASc <2 and No Contraindication	21	4	1	8
Structured+NLP with Contraindication	CHA ₂ DS ₂ -VASc ≥2 AND HAS-BLED <3 and Contraindication	2	0	0	1
	CHA ₂ DS ₂ -VASc ≥2 AND HAS-BLED ≥ 3 and Contraindication	6	2	0	1
	CHA ₂ DS ₂ -VASc <2 and Contraindication	0	0	0	0
Structured+NLP with No Contraindication	CHA ₂ DS ₂ -VASc ≥2 AND HAS-BLED <3 and No Contraindication	53	17	1	8
	CHA ₂ DS ₂ -VASc ≥2 AND HAS-BLED ≥ 3 and No Contraindication	113	13	0	23
	CHA ₂ DS ₂ -VASc <2 and No Contraindication	12	4	0	8

AI Biosurveillance: Population of NVAF in the USA

Population for Rates	Truven	Optum	Total	Event Rates in %
1. All the patients enrolled during Oct 2015 - Sep 2016	32,046,193	31,249,927	63,296,120	
2. (1) and age>=18 in 2016	25,400,465			
3. (2) and with any diagnosis of AF during Oct 2015 - Sep 2016 (first = index date)	422,092	865,072	1,287,164.00	
4. (3) and without VHD diagnosis during 1-year pre-index	355,811	611,990	967,801.00	1.52%
5. (4) and CHADS-VASc >= 2 and no contraindications to OAC	276,465	539,775	816,240.00	84.34%
6. (5) and Untreated	179,441	316,308	495,749.00	60.74%
Stroke Rate	11,530	10491	22,021.00	4.44%
Death Rate	727	593	1,320.00	5.99%

Cost the Year After Stroke	Costs the Year Prior to the Stroke	PMPM Difference	PMPM Inflation adjusted Difference	Annual PM Inflation adjusted Difference
\$11,130.30	\$2,665.40	\$ 8,464.90	\$ 8,253.42	\$ 99,041.00

Artificial Intelligence Based Disease Surveillance: The Case of NVAF

Extrapolated Results	Structured	Structured Plus Unstructured	Difference Between the Two Methods
NVAF Population	4,955,284	6,754,052	1,798,768
NVAF Population with no contraindications and CHA2DS2-VASc >= 2	4,543,995	6,193,466	1,649,470
NVAF Population needing Treatment	3,009,840	4,102,411	1,092,572
Strokes Prevented	133,637	182,147	48,510
Deaths Prevented	8,005	10,911	2,906
Cost Savings*	\$ 13,235,529,625.06	\$ 18,040,026,878.96	\$ 4,804,497,253.90

* Cost Basis is \$99,041 / Untreated Ischemic Stroke's 1st year after event Cost (1.9% Inflation Adjusted)

Strokes Prevented: Biosurveillance of NVAF patient cohorts CHA₂DS₂-VASC and HAS-BLED Scores using Natural Language Processing and SNOMED CT

Peter L. Elkin, MD, MACP, FACMII, FNYAM¹, Sarah Mullin, MS¹, Chris Crowner, MS¹, Sylvester Sakilay, MS¹, Shyamashree Sinha, MD MBA, MPH¹, Gary Brady, PharmD, MBA², Marcia Wright, PharmD², Kim Nolen, BS, PharmD², JoAnn Trainer, PharmD², Sashank Kaushik, MD, MBA¹, Jane Zhao, MD¹, Buer Song, MD, PhD¹, Edwin Anand, MD¹

¹University at Buffalo, Buffalo, NY; ²Pfizer, New York, NY

Circulation, 2017 Presented at the American Heart Association Meeting

Introduction

Nonvalvular Atrial Fibrillation (NVAF), is estimated to affect 5.8 million people in the US. NVAF results in a five times greater stroke risk. This study compared the accuracy of structured ICD9 vs. electronic health record (EHR) data including clinical note text using Natural Language Processing (NLP), to identify NVAF cases and the CHA₂DS₂-VASC and HAS-BLED Scores.

Methods

The retrospective EHR cohort study included patients of age 18 to 90 with a diagnosis of NVAF. Following application of the inclusion / exclusion criteria, an electronic model for structured data using ICD-9 criteria and for unstructured data using a NLP to SNOMED CT algorithm, a high throughput phenotyping system that rapidly assigns ontology terms to text in patient records, was applied to identify the NVAF population and their CHA₂DS₂-VASC and HAS-BLED Scores. A random sample of 300 patients was reviewed independently by two or three clinicians to create the gold standard NVAF cohort with CHA₂DS₂-VASC and HAS-BLED Scores.


Results

Out of the 96,681 patients identified in the AllScripts EHR data, 2.8% (2722 cases) were identified with NVAF by the Structured+NLP method as opposed to 1.9% for Structured alone (1849 cases) with a difference of 873 cases (32.1%, p<0.001). The sensitivity of the structured plus NLP method for the CHA₂DS₂-VASC and HAS-BLED was superior to the structured data alone (by 0.04, p=0.002 and 0.42, p<0.001 respectively). Clinical review showed that the untreated & met the criteria for treatment rate was 13.636%.

Conclusion

The Structured+NLP data extraction method had a higher sensitivity in comparison to Structured data alone, allowing for an increased number of true positive cases to be identified. If we extend these results nationally, this strategy could identify another 2,098,800 NVAF patients and an excess of 286,192 patients eligible for OAC Rx beyond ICD9 surveillance. This could prevent 11,448 strokes and save 687 lives at a savings of \$832,498,560 each year.

Figure 1. Histograms of CHA₂DS₂ Scores and HAS-BLED scores



ROC curve for Outcome Scores




Figure 2: ROC Curve for the CHA₂DS₂-VASC and HAS-BLED Surveillance using either the Structured or the Structured Plus Unstructured Methods

Conclusions


- Natural Language Processing is not only highly accurate, but also is now providing transaction speeds that make it practical for clinical applications.
- HTP-NLP is available for academic partnerships
- NLP is necessary to practically implement Semantic Interoperability
- Cross Validation of Data from a Variety of Datatypes is necessary to ensure accuracy
- Standardized Phenotypes can be shared and reused to ensure consistent population identification and data interoperability

Conclusions

- Clinical Decision Support assists clinicians in caring for their patients
- Biomedical Informatics partnering with Clinicians toward safer and more effective clinical care
- Biomedical Informatics as a Field deals with more than just computer in medicine
- Clinical Informatics is a new ABMS approved medical subspecialty that trains clinicians as future leaders of healthcare and healthcare organizations.


“...there is nothing more difficult to take in hand, more perilous to conduct, or more uncertain in its success, than to take the lead in the introduction of a new order of things. Because the innovator has for enemies all those who have done well under the old conditions, and lukewarm defenders in those who may do well under the new. “

Nicolo Machiavelli c. 1505

A large whale, likely a humpback, is captured mid-breach, its dark body arched high above the light blue ocean. The whale's white pectoral fin is visible on its left side. In the background, a distant shoreline with buildings and trees is visible across the water under a clear sky.

“The best way to predict the future,
is to create it.”

----- Peter Drucker
(Harvard University)



This program is supported by the National Center for Advancing
Translational Sciences of the National Institutes of Health under
award number UL1TR001412 to the University at Buffalo.

